Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $36.45, up 0.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The RARE shares have gain 9.23% over the last week, with a monthly amount glided 17.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] stock has seen the most recent analyst activity on October 20, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $65. On May 28, 2025, William Blair initiated with a Outperform rating. Goldman upgraded its rating to a Buy and increased its price target to $67 on June 06, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $77 as its price target on April 22, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $72.
Ultragenyx Pharmaceutical Inc [RARE] stock has fluctuated between $25.81 and $50.00 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $36.45 at the most recent close of the market. An investor can expect a potential return of 37.17% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 630.60M for the trailing twelve months, which represents a growth of 14.65%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.91%, and Net Profit Margin reading is -0.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -4.14 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.15 points at the first support level, and at 33.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.82, and for the 2nd resistance point, it is at 41.19.
Ratios To Look Out For
For context, Ultragenyx Pharmaceutical Inc’s Current Ratio is 1.89. On the other hand, the Quick Ratio is 1.74, and the Cash Ratio is 0.6. Considering the valuation of this stock, the price to sales ratio is 5.58, the price to book ratio is 383.12.
Transactions by insiders
Recent insider trading involved Horn Howard, Chief Financial Officer, that happened on Oct 13 ’25 when 7942.0 shares were sold. SVP, Chief Accounting Officer, Huizenga Theodore Alan completed a deal on Sep 18 ’25 to sell 64.0 shares. Meanwhile, Officer KARAH PARSCHAUER bought 2450.0 shares on Sep 12 ’25.
